Robert Holladay, MD
Pulmonary Disease · Shreveport, LANPI 1124023668
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.2%. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $30.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Pinnacle Biologics, Inc$4K
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$1K
- plus $7K from 54 others
Across 25 payments — averaging $1948.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gyrus ACMI, Inc.$34K
- Shionogi Inc$7K
- Spiration, Inc.$4K
- GSK$3K
- Merck$522
What the payments were for
- Consulting fees$4002%
- Speaking & faculty fees$1,5007%
- Travel & lodging$7,01731%
- Food & beverage$13,31360%
- Education$1080%
- Gifts$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,679
- Photofrin$3,437
- Olympus Bronchoscopes$839
- Olympus Capital Accessories$839
- Olympus Respiratory Accessories$839
- ZEPHYR ENDOBRONCHIAL VALVE$400
- PULMONX CHARTIS TABLET CONSOLE$400
- CHARTIS CATHETER$400
- ZEPHYR DELIVERY CATHETER$400
- Spin$280
- ILLUMISITE$149
- UPTRAVI$125
- Spiration Valve System$123
How this compares
$22,351 in reported general payments places this provider in the 90th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $108,171 |
| Dupixent PenDupilumab | 17 | $58,504 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,948 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 39 | $19,995 |
| Spiriva HandihalerTiotropium Bromide | 24 | $16,331 |
| Spiriva RespimatTiotropium Bromide | 21 | $15,897 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $14,289 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $7,598 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,442 |
| Advair DiskusFluticasone Propion/Salmeterol | 15 | $3,698 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $3,239 |
| Theophylline ErTheophylline Anhydrous | 15 | $1,851 |
| Ipratropium Bromide | 33 | $1,659 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,939 | $108,171132 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $1,009 | $50,18184 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,901 | $28,58648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Shreveport
- Scott HowardShreveport$20K
- David GreenShreveport$16K
- Himanshu DesaiShreveport$16K
- David ChambersShreveport$13K
- Ahmed ViraniShreveport$12K
- Ashley FerraroShreveport$10K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.